MedPath

A feasibility study to suppress myocardial [18F]-FDG uptake by pre-administration of pure caffeine

Conditions
cardiac inflammation
10028593
10003816
Registration Number
NL-OMON51725
Lead Sponsor
Erasmus MC, Universitair Medisch Centrum Rotterdam
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Pending
Sex
Not specified
Target Recruitment
8
Inclusion Criteria

Recent routine [18F]FDG PET/CT at Erasmus MC with inadequate myocardial
[18F]FDG suppression.
Signed informed consent
Extra-cardiac lesions
Age >= 18 years
Willing to undergo the study procedures

Exclusion Criteria

Pregnancy or breastfeeding
History of heart failure
Uncontrolled or untreated hypertension
Hypersensitivity for caffeine
Use of Methotrexaat, Adenosine, Stiripentol, Melatonin and/or B-blocker

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
<p>To investigate the effect of pure caffeine food supplement on myocardial<br /><br>[18F]FDG uptake suppression and extra-cardiac image quality between the study<br /><br>PET/CT and the routine PET/CT in the same patient.</p><br>
Secondary Outcome Measures
NameTimeMethod
<p>To monitor the safety and tolerability of pure caffeine food supplement in<br /><br>combination with [18F]FDG.<br /><br>To measure the effect of the additional caffeine on blood glucose and FFA.<br /><br>To gain insight in the physiological uptake pattern uptake due inadequate<br /><br>myocardial suppression.</p><br>
© Copyright 2025. All Rights Reserved by MedPath